Today, Danish pharmaceutical company Novo Nordisk begins the launch of its once-daily Wegovy pill in the United States. It will be available in 1.5 mg and 4 mg doses, priced at $149 per month for self-paying patients, a move set to revolutionize the weightloss market.
According to the company, this advancement opens new possibilities for the more than 100 million Americans living with obesity.
In a statement, Novo said, “Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.”
“Wegovy® pill is the first oral GLP-1 medicine for obesityin the US, and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. Wegovy® pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.”
Ed Cinca, SVP , Marketing & Patient Solutions at Novo Nordisk told investors, “We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy® in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment.”
He continued, “Wegovy® pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what’s possible in weight management, and to make that possible, we have worked to ensure Wegovy® pill is affordable and accessible to those who need it, however they choose to receive their care.”
Novo Nordisk shares jumped 3% following the announcement.
By CEO NA Editorial Staff
